Intravenous gammaglobulin‐associated acute renal failure

Gupta, Niraj; Ahmed, Imran; Nissel-Horowitz, S.; Patel, Dilip; Mehrotra, Bhoomi

doi:10.1002/1096-8652(200102)66:2<151::aid-ajh1035>3.3.co;2-h

Cited by 8 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The globulin is a purified protein fraction from human plasma; administration to patients with idiopathic thrombocytopenic purpura or Kawasaki disease has sometimes resulted in anaphylaxis or other allergic reactions. 19,20 The present case suggests that γ-globulin might also be able to cause a drug-induced hypersensitivity syndrome. However, it was ultimately difficult to elucidate which component of γ-globulin was responsible.…”

Section: Discussionmentioning

confidence: 67%

“…Tohyama et al 21 reported two adults with sulfasalazine-induced hypersensitivity associated with reactivation of HHV-6; anti-HHV-6 IgG titers in these patients showed a further increase on reexamination 2 weeks after the onset of the hypersensitivity symptoms. Suzuki et al 19 also described marked increases in anti-HHV-6 IgG 4 weeks after the appearance of symptoms in a patient with hypersensitivity syndrome induced by allopurinol. Latent HHV-6 infection appears to be reactivated in the course of drug-induced hypersensitivity; and the virus, in turn, can modify the disease course.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

An infant with γ-globulin-induced hypersensitivity syndrome who developed Evans' syndrome after a second γ-globulin treatment

et al. 2004

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 94%

An infant with γ-globulin-induced hypersensitivity syndrome who developed Evans' syndrome after a second γ-globulin treatment

et al. 2004

View full text Add to dashboard Cite

“…However, preexisting renal impairment, volume contraction and older age predispose to IGIV-induced renal complications [71]. These data indicate that approximately 90% of the patients who develop renal dysfunction receive an IGIV product that contains sucrose as a stabilizers explained above [69].…”

Section: Major Side Effectsmentioning

confidence: 96%

Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?

Abolhassani

Asgardoon

Rezaei

et al. 2015

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Immunoglobulin (IG) replacement therapy has served as lifesaving treatment in primary immunodeficiency diseases (PID) for more than six decades. Approximately 70% of patients with PID require IG replacement to maintain their health during the course of disease. It is estimated that about one-third of IG products is used for replacement therapy in these patients. On the other hand, the introduction of newer IG preparations is continuing to improve and extend the quality of life in PID patients. Because of the options available including concentrations, formulations, osmolality, product stabilizers, sodium concentration, anti-infective activity, IgA content and pH, it is important to match the PID patient's complications with potential side effects associated with the composition of a particular IG product. The purpose of this review is to present the clinical differences of intravenous IG among the various preparations regarding PID patients.

show abstract

“…However, significant adverse events including renal dysfunction [19][20][21][22] and serious thrombotic complications [23] have been associated with IVIG therapy. The associated renal dysfunction seems to be related to the high osmolarity of sucrose containing IVIG preparations [24] while rapid infusion of IVIG is an apparent risk factor for thromobotic complications.…”

Section: Desensitization With High Dose Ivigmentioning

confidence: 99%

Modulating Alloimmune Responses with Plasmapheresis and IVIG

Warren¹,

Simpkins²,

Cooper³

et al. 2005

CDTCHD

View full text Add to dashboard Cite

Antibody-mediated barriers to renal transplantation, including donor specific anti-HLA and anti-blood group antibodies, have become an increasingly important issue over the last forty years as the organ shortage has continued to expand. The inevitable result of the unmet demand for compatible organs has been a continuous increase in recipient waiting times. Over the last decade, two treatment strategies have been developed to address this problem. These regimens rely on the immunomodulatory properties of intravenous immunoglobulin (IVIG) administered alone at relatively high doses, or at lower doses in combination with the non-selective depletion of antibodies from plasmapheresis. Both protocols have been successfully used for desensitization of patients with donor-specific anti-HLA antibody and have allowed for renal transplantation with excellent outcomes. The combined strategy of plasmapheresis/IVIG has also been successfully employed for renal transplantation in recipients of ABO blood group incompatible kidneys. This review will provide an overview of these therapies and their application to incompatible renal transplantation.

show abstract

Intravenous gammaglobulin‐associated acute renal failure

Cited by 8 publications

References 0 publications

An infant with γ-globulin-induced hypersensitivity syndrome who developed Evans' syndrome after a second γ-globulin treatment

An infant with γ-globulin-induced hypersensitivity syndrome who developed Evans' syndrome after a second γ-globulin treatment

Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?

Modulating Alloimmune Responses with Plasmapheresis and IVIG

Contact Info

Product

Resources

About